Ablynx

@AblynxABLX

Ablynx is a biopharmaceutical company engaged in the discovery and development of Nanobodies® for a range of serious human diseases.

Ghent/Zwijnaarde, Belgium
ablynx.com
Bergabung Mei 2012
5 Foto dan video Foto dan video

Tweet

Anda memblokir @AblynxABLX

Yakin ingin melihat Tweet ini? Melihat Tweet tidak akan membuka blokir @AblynxABLX

  1. me-Retweet
    26 Jul

    FDA designates top nanobody caplacizumab fast track designation: 6-10 months faster approval

    3 retweet 4 suka
  2. me-Retweet
    20 Jul

    2.4bn "bioeuro": Belgian Nanobody delights now also tasteful in France

    2 retweet 7 suka
  3. 20 Jul

    and Sanofi to develop up to 8 Nanobody®-based therapeutics focused on immuno-inflammatory diseases

    1 balasan 9 retweet 14 suka
  4. 27 Jun

    achieves second milestone in immuno-oncology collaboration with Merck & Co., Inc.

    7 retweet 16 suka
  5. 26 Jun

    initiates a single and multiple dose Phase I study of caplacizumab in healthy Japanese subjects

    4 retweet 6 suka
  6. 29 Mei

    launches , a new website dedicated to Thrombotic Thrombocytopenic Purpura (TTP)

    10 retweet 9 suka
  7. 22 Mei

    receives €15M milestone from Merck KGaA for novel Nanobody in osteoarthritis

    10 retweet 12 suka
  8. 18 Mei

    Meet our experts and recruiters (booth 99) @

    2 suka
  9. 11 Mei

    Ablynx zit op schema via

    4 retweet 6 suka
  10. 11 Mei

    Q1 2017 "Positive start of the year; good progress in multiple programmes; strong cash position"

    6 retweet 4 suka
  11. 10 Mei

    Publication in Journal of Thrombosis and Haemostasis "Caplacizumab reduces major thromboembolic events"

    7 retweet 7 suka
  12. 2 Mei

    successfully completes patient recruitment in its Phase III Hercules study of caplacizumab

    2 retweet 6 suka
  13. 7 Apr

    Annual Report 2016 is available online - view via

    1 retweet 4 suka
  14. 7 Apr

    - Adrianus van Herk (aandeelhouder Ablynx): 'België en Nederland zijn wereldtop' via @trends

    1 retweet 4 suka
  15. me-Retweet
    6 Mar

    Compelling data for developed psoriasis nanobody in collaboration

    3 retweet 2 suka
  16. me-Retweet
    28 Feb

    Good morning to those waking up in Europe, Africa and the Middle East! Share with us what you have planned for today!

    15 balasan 51 retweet 103 suka
  17. me-Retweet
    24 Feb

    you will find out that is dedicated to creating new medicines which will make a real difference to society!

    1 retweet 1 suka
  18. 23 Feb

    FYR 2016: significant progress in R&D pipeline; strong cash position; major catalysts in 2017.

    4 retweet 3 suka
  19. 9 Feb

    will present additional data from the Phase IIb RA combination study of vobarilizumab at the Annual CRA Meeting

    2 retweet 2 suka
  20. 6 Feb

    Ablynx files caplacizumab for ultra rare blood disorder
    6 retweet 9 suka

@AblynxABLX masih belum menge-Tweet.

Pemuatan tampaknya berlangsung agak lama.

Twitter sedang kelebihan beban atau mengalami sedikit masalah. Coba lagi atau kunjungi Status Twitter untuk informasi lebih lanjut.

    Mungkin Anda juga suka

    ·